Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Share-based Compensation (2019 - 2026)

Pliant Therapeutics has reported Share-based Compensation over the past 8 years, most recently at $4.3 million for Q1 2026.

  • Quarterly Share-based Compensation fell 52.27% to $4.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $21.6 million through Mar 2026, down 41.49% year-over-year, with the annual reading at $26.2 million for FY2025, 30.28% down from the prior year.
  • Share-based Compensation was $4.3 million for Q1 2026 at Pliant Therapeutics, down from $4.5 million in the prior quarter.
  • Over five years, Share-based Compensation peaked at $13.0 million in Q2 2023 and troughed at $3.4 million in Q2 2022.
  • The 5-year median for Share-based Compensation is $8.9 million (2024), against an average of $8.0 million.
  • Year-over-year, Share-based Compensation surged 292.16% in 2022 and then tumbled 52.27% in 2026.
  • A 5-year view of Share-based Compensation shows it stood at $10.9 million in 2022, then fell by 15.69% to $9.2 million in 2023, then fell by 8.03% to $8.4 million in 2024, then tumbled by 46.24% to $4.5 million in 2025, then dropped by 5.99% to $4.3 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Share-based Compensation are $4.3 million (Q1 2026), $4.5 million (Q4 2025), and $6.4 million (Q3 2025).